• ABPI Website
  • Media
  • ABPI statement on the death of Professor Sir Michael Rawlins GBE Kt

ABPI statement on the death of Professor Sir Michael Rawlins GBE Kt

ABPI offers the industry’s condolences following the death of Professor Sir Michael Rawlins GBE Kt

Sir Michael was a leading figure in public health and made an enormous contribution to medicine and clinical pharmacology. Richard Torbett, ABPI Chief Executive

Following the sad news of the death of Sir Michael Rawlins GBE Kt, former Chairman of NICE and the MHRA and past President of the Royal Society of Medicine, Richard Torbett, ABPI Chief Executive, said:

“The ABPI and the pharmaceutical industry in the UK would like to express our condolences to Sir Michael’s family, friends, and all those that knew him during this difficult time.

“Sir Michael was a leading figure in public health and made an enormous contribution to medicine and clinical pharmacology.  He provided inspirational leadership as the Chair of the MHRA and the Founding Chair of NICE, where he was successful in building a globally renowned world-leading organisation for assessing health and social care innovations and evidence-based practice”.

“Sir Michael has had a lasting impact on NHS patient care and played a key role in championing the UK’s life science sector. He will be profoundly missed.”

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.